Peter Boros, Genetic Immunity's President presented the Company's pDNA-based platform technology and clinical trial data relating to HIV in front of an esteemed gathering of HIV experts. As part of the presentation, Genetic Immunity announced the launch of a Phase III clinical trial for the company'